Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Malcolm on American scene today about 17 minutes in the show Malcolm talks, takes about 10 minutes to down load I think its a repeat ?
http://archives.warpradio.com/btr/AmericanScene/081709.MP3
Very good news the market makers are trying to shake the tree before good news.
This much trading means news may hit the wires about noon.
WOW could CYTOGENIX be the company to save the day ?They have solved the delivery problem for sepsis ,great Googling Suky ,its time for our little company to bloom .We need Cytogenix technology now, not in 6 months ,fast track has to be considered.If we are not considered the people of the world will suffer .I am more amazed every day that this little biotech company has not been interviewed by a major news network with this next generation technology .Its only a matter of time, one day you will turn on the TV and view world news about Cytogenix,and I think its very close to that time.{Look forward to a healthy future }should be CYGX motto.
sukycospito tried to google on Dr Charles Densmore trying to find that article that he wrote a paper on the aerosole delivery using Cytogenix technology .I remember the article had a picture of Densmore ,I was just thinking is it still in print.
Eightball you go and redeem yourself on the Raging bull board with an intelligent message. Why can,t you write good posts over here.
apeball you are looking more and more like a turd of a basher ,you contributed nothing to this board ,your past posts are nothing but a waste land of thought ,and I read them all.Either you are incapable of any independent thought or you are a clever actor .I gave you a chance to redeem your self but you showed your colors.You, lawrence and HRM on the raging animal board make a good team.
eightball, skooby posted 4 hours after the storm ,and lots of people had power and lots did not have power after the storm ,yes skooby is a visionary he was correct to hold his ground during the storm of both natural and financial decisions.And whats wrong with this picture , eightball you come down on people yet bring little information to this board ,I just wish you could bring something anything try Google .
I think in a few years a dollar a share will be considered buying low.I am ok with my average share price of being .57 cents a share I bought low, I bought high ,and I am buying now .I may average down even more in the next few weeks fingers crossed.
Arnold you are correct I listened again the Pharmas are there waiting for clinical trials to end , and then the fun begins.Arnold lots of information in the interview did you pick up on any other thoughts that may be of interest in the interview.
Wall Street Reporter interview is excellent, Malcolm states that we Cytogenix will be at the center of all pharma genomic in 5 years ,and that big Pharma companies are ready to jump on board.People our technology works and it works so well none of the insiders sold not one share.Listen to this interview and listen again.
http://www.wallstreetreporter.com/profiles/CytoGenix.html
skoobyfl1 is correct on this one again.
I am just glad they took my advise and put out a PR .The CEOcast interview has lots of good information .Read post 10175 .and 10202
Malcolm on American scene today half way through takes about 10 minutes to down load he talks about the patents.
http://archives.warpradio.com/btr/AmericanScene/081209.MP3
Holycow Its from the CEOcast interview on the page as you are listening you can read all about it.You have to log in or register for free.
http://www.ceocast.com/company.cfm?cid=1105&n=111117
Some new information
Therapeutic Gene Blocking Topical Applications
CytoGenix has developed antisense and DNA enzymatic systems to down regulate or “turn off” proteins involved in Herpes, Inflammatory processes such as psoriasis and Alopecia (pattern baldness). The Company has combined these DNA systems into creams and lotions for topical application. Animal toxicology tests have shown no negative effects.
The Company believes that the Anti-inflammatory formulation could provide relief to outbreaks of shingles lesions and inflammation due to Psoriasis.
Pre-clinical (animal) studies
The company will begin conducting animal studies at a major cancer center and an academic medical center in collaboration with senior scientists in anticipation of an Investigational New Drug (IND) application to the FDA and subsequent human trials for at least two of these topical preparations. These animal and laboratory studies are designed to demonstrate biological activity and safety of a DNA topical cream and lotion for herpes and contact dermatitis.
The Company intends to engage a firm of FDA consultants as well as a contract research organization (CRO) at the appropriate stages of clinical trials. The following is a projected timeline for regulatory submission activities for two or possibly three indications for transdermal delivery.
Depending on the success of Phase I studies, the Company intends to begin animal studies on DNA topicals against melanoma or HPV the virus that causes most cervical cancers.
Toxicity
The Company believes that unlike synthetic chemicals, these DNA topical lotions and creams will have very low toxicity and side effects because:
They are applied only to the infected site and not systemically throughout the body.
The “active” ingredient is natural DNA created by the cells, not a synthetic chemical.
The carrier cream has been used widely for many years in animal and human health topical applications and is very safe and non-toxic.
Dosage levels are very low (see No. 2 above).
The Company will strive to demonstrate to regulatory agencies that DNA transdermal delivery in small dosages is highly specific, effective and non-toxic.
INSTITUTIONAL OWNERSHIP/ANALYST COVERAGE
Institutional Investors:
• CSI Capital Management, Inc.
• Patten & Patten, Inc.
Analyst Coverage:
J.M. Dutton & Associates
• Sherry Grisewood , CFA
Yes thank texguy lots of companies put out a press release or PR stating they will be on ceocast its news and informative, but for some reason Cytogenix thought it not news worthy.
Peace, Malcolm said look for news on funding 30 to 60 days that would put us past the summer dulldrums and great news just may hit the wire in a couple of weeks remember Baylor ,Phanuel,and the Goverment looking for new independent application drugs.
The ask was .28 all day 90% buys the ask doesn't move,I wonder if it was 90% sell how much they would have lowered it ,probably tomorrow will be tree shaking day so they will try to buy back the shares they did not have today that they sold.More and more steady hands are holding CYGX I think it will be difficult to find cheap shares tomorrow.
Close to all buys today and one last minute sell of 3000 shares at .26 Market Maker ACAP sold shares they did not have how are they going to cover their short position.90% buys and they still don't want to move up the ask to .29
Other companies PR the fact that They are interviewed on CEOcast.
http://biz.yahoo.com/bw/040810/105674_1.html
Malcolm on American scene today 1/3 the way he speaks of Balor and the lung cancer treatment is going well.Very good interview takes about 8 minutes to down load.
http://archives.warpradio.com/btr/AmericanScene/080909.MP3
Doxi do you know the whole biotech sector is way down?These are the times that millionares are made .Low prices like these are a gift ,don't let this opportunity pass you by.So your logic is every time stock prices drop its managements fault ,not short sellers ,not bashers ,not week knee day traders ,not the calm before the storm ,not the otcbb,not that people in general are uneducated idiots that could not see a good thing if it jump up on them.
Doxi yes they are rumors probably supply by some basher ,all is well .
As part of the important Drug Target Validation Service, CYGX is the sole pioneer in developing novel business structures to effectively combine leading edge biotechnology with traditional pharmacology through PharmaGenix, LLC, a joint enterprise with the Professional Compounding Centers of America, and their nearly 3,000 member compounding pharmacists.
It may well be that many previously incurable diseases will be cured through the gene therapy. CytoGenix, Inc. will play a vital role in this effort because of the insight of the company's leadership. CEO Malcolm Skolnick understands and agrees with an observation made long ago:
We know our ssDNA expression system works." said CEO Skolnick," The proof of concept phase is over. We are now ready to develop our broad-based technology into important therapeutics to eliminate or ameliorate specific disorders."
Not a single share has been sold by management and staff that tells us a lot, these people know what they have and are in for the big return.
Eight the whole bio tech market is down now, if you got the balls to buy low this is the perfect time but most people don't .Thats why there is so few millionares .Listen to all the interviews then listen again if you don't buy more while the buying is good then you only have yourself to blame.If you are one of those day traders that bought high, now is your chance to average down ,Malcolm is looking for long term people that will hold the stock stable, are you one? One thing that hurts this company is day traders that come on this board announce they finally sold and leave a turd of a remark about CYGX like a dog before they leave. These are the idiots that CYGX doesn't need, these are the makers of instability that bought high and sell low.They are slowly being weeded out and replaced with long term people.Don't be afraid of a long term commitment these are the ones that pay off big time in the long run.
Skoobyfl1 you are so correct I say 98% of this stock is held by very smart and very long term people with vision that can see that the future holds Cytogenix in a very high place.Once the last of the day traders are gone and CYGX will be totally held by visionaries this stock will rocket.Malcolm said we want people who understand Cytogenix technology to buy our stock that will cause a stable stock .Intelligent people = long term people= stability =high PPS = very very good retirement plan.
ddillybbass you are starting to leave turds on this board like a basher would do .If you want a war I will go to your FLCR board and start showing the negatives of your FLCR,your choice .If you don't own CYGX anymore then stay on FLCR.When you are over on this board if you can't bring anything positive then you start to looking like a LO.
bbillybbass nice sound effects but your FLCR looks like a classic pump and dump and you can't even see how many shares the company is dumping very dangerous to own, in order to trust these people you would have to be in the office to know whats going on lets hope you won't need your sound effects for FLCR.
kevb I read Skoob post again and it was not terrible ,it was the truth and where is it written you shall not judge other people stock picks.LOL
bbillybbass did you see the financials of FLCR it looks bad, do you see a good picture here?
RESULTS OF OPERATIONS FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2004 AND 2003
Revenues during the three months ended March 31, 2004 were $2,881 with cost ofsales of $506 yielding gross profit of $2,375. Operating expenses and generaland administrative costs during this period were $267,496 and interest expensewas $8,043 resulting in a net loss from continuing operations of $273,164.
For the three months ending March 31, 2003, FullCircle had revenues of $244,886and cost of sales of $84,593 resulting in gross profit of $160,293. However,operating expenses and general and administrative costs for the same period were$432,789 resulting in an operating loss of $272,496. Interest expense duringthis period was $20,563. As a result, FullCircle realized a net loss fromcontinuing operations of $293,059 for the three months ended March 31, 2003.
Revenues declined significantly during the first quarter of 2004 compared to thefirst quarter of 2003. This decrease is due to the fact that on July 29, 2003,the Company entered into a sales agreement for its wholly owned subsidiary,Paradigm Solutions Group, L.L.C. (Paradigm). During the first quarter, 2003 theCompany had generated significant sales through its Paradigm subsidiary, whichhad an existing client base of employers utilizing its health reimbursementmodel.
bbillybbass sorry to hear that you needed money and you had to sell your shares of Cytogenix ,I have been buying at these levels I hope I never get into a situation that I need to sell my future for some present bill due. Hope you are able to get back in before the train leaves.A stock picker on the American scene today said that the Bio teck market is ripe for explosive growth ,all I could think of is that Cytogenix is ready .
Tatonkano62 another great interview on American scene today half way through very very very good herpes and sepsis are neck to neck going to FDA .About 10 min to down load its worth it.
http://archives.warpradio.com/btr/AmericanScene/080409.MP3
Holycow 7000 shares traded .32 to duy and .29 to sell all buys so far sits at .32.
Charles Densmore Jr., Ph.D.
Assistant Professor, Department of Molecular Physiology & Biophysics
Ph.D., University of Florida College of Medicine
Postdoctoral, Baylor College of Medicine
E-mail: charlesd@bcm.tmc.edu
Telephone: (713) 798-3603
Fax: (713) 798-3475
Research Interests
The development of polymer-based aerosol gene delivery technology for the treatment of cancer, cystic fibrosis, alpha-1-antitrypsin deficiency, diabetes and a wide range of other pulmonary genetic disorders.
Over the last several years, efforts have been focused on the development of aerosol nonviral gene delivery technology for the treatment of lung cancer and a variety of other pulmonary genetic disorders. This has involved finding appropriate nonviral DNA delivery vectors that both withstand the sheer forces of nebulization and also function optimally in the environment of the lungs and airways. This innovative and noninvasive approach to gene delivery must overcome a number of physiological and structural barriers which have, to date, limited success clinically. The screening of a wide range of cationic lipids and polymers has resulted in candidates that exhibit remarkably high transfection efficiencies in airway epithelial and other lung cells and have yielded very significant biological responses in both antitumor and genetic immunization studies. This noninvasive mode of delivering genes now appears to be associated with only a minimal immune response and low overall toxicity and results in gene expression detectable up to a month after a single aerosol exposure. Current efforts primarily involve the aerosol delivery of polyethylenimine-based formulations of a variety of tumor suppressor and cytokine genes for the treatment of several human and murine lung tumor models in mice. The delivery of polymer-based gene silencing formulations represents another ongoing government/industry-funded effort. We are also investigating the idea of combining gene, chemo- and radio-therapies to treat these and other cancers. In addition, the application of this technology to treat other pulmonary conditions such as asthma, alpha-1-antitrypsin deficiency and cystic fibrosis is being pursued through a number of collaborative efforts here at Baylor, at the M. D. Anderson Cancer Center and elsewhere in academia and in industry.
Selected Publications
Kinsey B, Densmore C, Orson F. (2004). Gene delivery to the lungs by polycations. Polymeric Gene Delivery: Principles and Applications. Edited by M. M. Amiji. (In Press)
Kinsey B, Densmore C, Orson F. (2004). Non-Viral Gene Delivery to the Lungs. Current Gene Therapy (accepted).
Densmore, CL. (2003). Polyethyleneimine-based Gene Therapy by Inhalation. Expert Opinion in Biological Therapy. 3(7):1083-1092.
Densmore, CL. (2003). The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy. Current Cancer Drug Targets. 3(4):275-86.
Jia SF, Worth LL, Densmore CL , Xu B, Duan X, Kleinerman ES. (2003). Aerosol gene therapy with PEI:IL-12 eradicates established osteosarcoma lung metastases. Clinical Cancer Research. 9(9):3462-8.
Koshkina NV, Agoulnik I, Melton S, Densmore CL, Knight V. (2003). Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. Molecular Therapy. 8(2):249-54.
Densmore CL, Gautam A, Waldrep JC, Knight V. (2002). Re-establishing gene therapy by aerosol using transfection-efficient, low toxicity DNA-polymer constructs. Respiratory Drug Delivery. 8:1-7.
Densmore CL, Kleinerman ES, Gautam A, Jia SF, Xu B, Worth LL, Waldrep JC, Fung YK, T'Ang A, Knight V. (2001). Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Therapy. 8(9):619-27.
Densmore CL, Orson F, Xu B, Kinsey BM, Waldrep JC, Hua P, Bhogal B, Knight V. (2000). Aerosol delivery of robust PEI-DNA complexes for gene therapy and genetic immunization. Molecular Therapy. 1(2):180-8.
Contact Information
Charles Densmore Jr., Ph.D.
Department of Molecular Physiology and Biophysics
Baylor College of Medicine
One Baylor Plaza, BCM 335
Houston, Texas 77030
Telephone: (713) 798-3603
Fax: (713) 798-3475
E-mail: charlesd@bcm.tmc.edu
Cytogenix And Baylor College of Medicine to Conduct Pre-Clinical Testing Of An Aerosol Gene-Silencing Agent Against Cancer In The Lung
HOUSTON--(BUSINESS WIRE)--Jan. 21, 2004--CytoGenix Inc. (OTCBB:CYGX - News) has entered into an agreement with scientists at Baylor College of Medicine for experiments using a combination of the company's ssDNA expression vector technology and Baylor's proprietary aerosol gene delivery technology against a gene that, when silenced, inhibits tumor metastasis.
Dr. Charles L. Densmore, assistant professor, department of molecular physiology and biophysics, will direct these studies to determine the effect this novel gene delivery and silencing system has on cancer in the lungs of mice. Dr. Densmore is the inventor of this aerosol gene delivery system. He has pioneered its use for lung cancer, asthma and other pulmonary disorders.
Dr. Densmore stated, "The combination of these technologies has great potential for treating metastatic lung cancers and other difficult to treat pulmonary disorders. Our aerosol technology is non-invasive, and delivers directly to airway epithelial and pulmonary surfaces, thus avoiding many of the problems associated with intravenous delivery such as interaction with serum proteins, and difficulties in penetrating lung endothelial barriers."
Dr. Malcolm Skolnick, chairman and CEO of CytoGenix, stated, "We are very excited about the potential development of a very important clinical application of our ssDNA expression vector. Metastatic lung tumors are important targets because several cancers such as melanoma, breast and prostate tend to metastasize in the lungs."
CytoGenix Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a U.S. patent for its core DNA expression technology and has 40 international or U.S. pending patent applications.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the Web site at www.cytogenix.com.
Contact:
CytoGenix, Houston Juan Ferreira, 407-774-9949
Source